A team of scientists in Germany has developed a new blood test that could help doctors identify Alzheimer’s disease and Parkinson’s disease years before patients begin showing symptoms.
Researchers say the discovery could lead to earlier treatment and better chances of slowing these devastating brain disorders.
The research was carried out by scientists led by Professor Klaus Gerwert from Ruhr University Bochum.
The study was published in The Journal of Physical Chemistry B and was featured as the journal’s cover story on April 24, 2026.
Alzheimer’s disease and Parkinson’s disease are among the most feared illnesses linked to aging. Alzheimer’s slowly damages memory, language, reasoning, and daily functioning. Parkinson’s disease affects movement and may cause shaking, slow movement, stiffness, and difficulty walking.
Both diseases become more common with age, and the number of patients worldwide is growing quickly as people live longer than before.
One of the biggest difficulties in treating these illnesses is that diagnosis often happens too late. By the time symptoms become obvious, the brain may already be badly damaged. In Alzheimer’s disease, large numbers of brain cells may already have died before memory problems become noticeable.
Scientists now believe that harmful changes inside the brain begin many years, or even decades, before symptoms appear. This has led researchers around the world to focus on finding methods for earlier detection.
According to Professor Gerwert, many experts agree that future treatments need to start before visible brain damage develops. Early diagnosis could allow doctors to begin treatment at a stage when the brain is still healthier and more responsive.
The new blood test focuses on detecting abnormal proteins connected to Alzheimer’s and Parkinson’s disease.
In Alzheimer’s disease, the researchers study a protein called amyloid beta. In healthy people, this protein normally exists in harmless forms. But in Alzheimer’s disease, the protein changes shape and begins forming sticky deposits known as amyloid plaques inside the brain.
In Parkinson’s disease, another protein called alpha-synuclein becomes abnormal and forms clumps called Lewy bodies. These protein clumps damage brain cells and interfere with normal brain communication.
The German research team created a highly advanced sensor system designed to detect these damaged proteins directly from blood samples.
The technology uses special antibodies that recognize and capture the abnormal proteins. Once the proteins are isolated, scientists use infrared spectroscopy and powerful quantum cascade lasers to examine the proteins’ structure in great detail.
The system is sensitive enough to identify very small molecular changes linked to disease development.
The researchers also developed a patented chemical surface that helps prevent unrelated substances in blood from interfering with the test results. This allows the sensor to focus specifically on the disease-related proteins.
Lead author Dr. Grischa Gerwert said the technology combines several scientific fields, including molecular biology, laser physics, and biophysics. According to the researchers, this interdisciplinary approach helped make the new test possible.
One major advantage of the technology is that it may eventually be scaled up for use in large healthcare systems. The laser-based method allows many samples to be tested simultaneously, which could make routine screening more realistic in the future.
The test is already being used in clinical research through the company BetaSENSE, founded by members of the research team. The company currently works with pharmaceutical companies to evaluate new treatments for neurodegenerative diseases, including experimental vaccines for Parkinson’s disease.
Researchers say the long-term goal is to make the blood test available as a preventive screening tool for the general public. However, the test still requires approval under European medical regulations before it can be widely used in hospitals and clinics.
The approval process involves extensive safety testing, quality control, and regulatory review. The researchers say they are continuing to work toward making the test available as soon as possible.
The findings offer hope that future healthcare may shift from late-stage treatment toward prevention and earlier intervention. A simple blood test could one day allow doctors to identify people at risk before major brain damage occurs.
At the same time, experts caution that more research is still needed. Scientists must confirm how accurately the test predicts future disease and determine how doctors should respond to positive results in patients who have no symptoms yet.
Overall, the study represents a promising development in the growing effort to detect neurodegenerative diseases earlier and improve long-term outcomes for aging populations.
If you care about Parkinson’s disease, please read studies that Vitamin B may slow down cognitive decline, and Mediterranean diet could help lower risk of Parkinson’s.
For more health information, please see recent studies about how wheat gluten might be influencing our brain health, and Olive oil: a daily dose for better brain health.
